We concluded that the 10 cmH2O of PEEP attenuates the effects of PnP in respiratory mechanics, lowering R(RS), E(P), and E(RS). These effects may be useful in the ventilatory approach for patients experiencing a non-physiological increase in IAP owing to PnP in laparoscopic procedures.

Clinicaltrials.gov identifier: NCT01804205.

No abstract

SummaryMagnesium potentiates neuromuscular blockade. Sugammadex reverses rocuronium-induced blockade. The aim of this study was to determine the effect of pre-treatment with magnesium sulphate on sugammadex reversal time for neuromuscular blockade. Seventy-three patients were randomly assigned to receive magnesium sulphate (40 mg.kg À1 ) or saline intravenously. After anaesthetic induction, continuous train-of-four monitoring was performed and rocuronium was administered (0.6 mg.kg À1 ). When a second twitch appeared, the patients received sugammadex (2 mg.kg À1 ).

Propofol protected cells against apoptosis induced by I-R. This protection was probably due to a preconditioning effect of propofol and was, at least in part, mediated by K(ATP) channels.

RESUMO RESULTADOS:Os tipos de dor encontrados foram nociceptiva, neuropática e incidental, avaliadas utilizando-se a escala unidimensional de faces. Verificou-se a analgesia controlada pelo paciente (PCA) com metadona, via oral, em ambiente domiciliar na 1ª semana. Após esse período, o paciente retornava ao ambulatório para o cálculo da dose regular da metadona. Outros opióides utilizados foram codeína, tramadol, morfina e oxicodona. Além da dor, os pacientes apresentaram: constipação, náuseas, vômitos, delirium, alteração do sono e dispnéia. Os neurolépticos, corticóides e laxantes foram usados como fármacos adjuvantes. CONCLUSÕES: A analgesia controlada pelo paciente utilizando a metadona mostrou-se segura e eficaz pela não-ocorrência de efeitos colaterais significativos. O conhecimento clínico e farmacológico do anestesiologista na equipe multiprofissional proporcionou melhor atendimento para o alívio dos sintomas dos pacientes e humanização no período final de vida.

No abstract

Objectives: The use of magnesium sulfate in the perioperative period has several benefits, including analgesia, inhibition of the release of catecholamines and prevention of vasospasm. The aim of this survey was to provide an overview of the use of magnesium sulfate in anesthesia. Method: This was a prospective descriptive cross-sectional study. An online questionnaire was sent to 9,869 Brazilian anesthesiologists and trainees. The questionnaire comprised closed questions mainly regarding the frequency, clinical effects, adverse events, and doses of magnesium sulfate used in anesthesia. Results: Of the 954 doctors who responded to the survey, 337 (35.32%) reported using magnesium sulfate in anesthesia. The most commonly cited clinical effects for the use of magnesium sulfate in anesthesia were ( n /%): postoperative analgesia (245/72.70%), reduction of anesthetic consumption (240/71.21%) and prevention and treatment of preeclampsia and seizures in eclampsia (220/65.28%). The most frequently reported adverse events were hypotension (187/55.48%), residual neuromuscular blockade (133/39.46%), hypermagnesemia (30/8.90%), and intravenous injection pain (26/7.71%). The intravenous doses of magnesium sulfate used in most general anesthesia inductions were between 30 and 40 mg.kg −1 . Conclusions: Magnesium sulfate is an important adjuvant drug in the practice of anesthesia, with several clinical effects and a low incidence of adverse events when used at recommended doses.